Faculty Opinions recommendation of Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

2002 ◽  
Author(s):  
René Hen
Keyword(s):  
Receptor Antagonist ◽  
Innovative Approach ◽  
V1b Receptor

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior

2014 ◽  
Vol 730 ◽  
pp. 157-163 ◽  
Author(s):  
Robert A. Hodgson ◽  
Deborra Mullins ◽  
Sherry X. Lu ◽  
Mario Guzzi ◽  
Xiaoping Zhang ◽  
...  
Keyword(s):  
Animal Models ◽  
Receptor Antagonist ◽  
V1b Receptor ◽  
Animal Models Of Anxiety

scholarly journals A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

2016 ◽  
Vol 42 (5) ◽  
pp. 1012-1023 ◽  
Author(s):  
Megan L Ryan ◽  
◽  
Daniel E Falk ◽  
Joanne B Fertig ◽  
Beatrice Rendenbach-Mueller ◽  
...  
Keyword(s):  
Alcohol Dependence ◽  
Randomized Trial ◽  
Receptor Antagonist ◽  
Phase 2 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
V1b Receptor

The Non‐Peptide Vasopressin V1b Receptor Antagonist, SSR149415, Ameliorates Spermatogenesis Function in a Mouse Model of Chronic Social Defeat Stress

2017 ◽  
Vol 118 (11) ◽  
pp. 3891-3898 ◽  
Author(s):  
Bin Wang ◽  
Jian Zhou ◽  
Yan‐Yan Zhuang ◽  
Liang‐Liang Wang ◽  
Jin‐Xian Pu ◽  
...  
Keyword(s):  
Mouse Model ◽  
Receptor Antagonist ◽  
Social Defeat ◽  
Social Defeat Stress ◽  
Chronic Social Defeat Stress ◽  
V1b Receptor
Sign in / Sign up

Export Citation Format

Share Document